PTC Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
PTC Therapeutics, Inc. (PTCT) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $60.27 million as of 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2025-02-27
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $60.27M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $69.96M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $76.59M.
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $17.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2023-12-31 | $60.27M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $69.96M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $76.59M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $17.00M 10-K · filed 2022-02-22 | |
| 2019-12-31 | $91.01M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $62.16M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $61.07M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $80.06M 10-K · filed 2018-03-06 | |
| 2015-12-31 | $75.20M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $76.93M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $88.19M 10-K · filed 2015-03-02 | $88.19M 10-K · filed 2014-03-06 |
| 2012-12-31 | $71.75M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |